Creatine Kinetics, Synthesis From Glycine and Response to Creatine and Amino Acid Supplement in Healthy Humans
The goal of the present study is to quantify the rate of synthesis of creatine in healthy controls and endurance trained subjects. In addition, the effect of oral creatine supplement for seven days on creatine kinetics will be examined.
Ten healthy controls (age 20-35 years) and ten endurance trained subjects will be recruited by advertisement. Endurance trained subjects will be recruited from health clubs. They will be screened for absence of any chronic disease (history, physical examination, CBC, metabolic and liver panel, urinalysis). A DEXA measurement will be done to quantify whole body skeletal muscle mass.
For five (5) days prior to the study, they will be placed on a creatine-free (essentially meat-free) diet. Dietary compliance will be ensured by repeated communication with the subject, by nurse coordinator and the CRU Nutritionist. Subject will maintain daily record of the food intake for validation. On the last day, i.e. 24 hours prior to the tracer study, subject will collect the 24 hours urine sample and bring it to the CRU on the day of the study.
Creatine Synthesis in Healthy Subjects
Dietary Supplement: Creatine and Amino Acid supplement
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
|Official Title:||Creatine Metabolism in Humans:Effect of Creatine and Amino Acid Supplement|
- Quantification of creatine synthesis in healthy subjects [ Time Frame: 12/31/2012 ] [ Designated as safety issue: No ]
- Effect of creatine supplement on the rate of creatine synthesis [ Time Frame: 12/31/2012 ] [ Designated as safety issue: No ]
|Study Start Date:||January 2010|
|Study Completion Date:||December 2013|
|Primary Completion Date:||June 2013 (Final data collection date for primary outcome measure)|
|Experimental: Creatine and amino acid supplement||Dietary Supplement: Creatine and Amino Acid supplement|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01725503
|United States, Ohio|
|Cleveland, Ohio, United States, 44195|
|Principal Investigator:||Satish Kalhan, MD||The Cleveland Clinic|